Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.37 ▼ -0.02
(-5.43%)
MKT CAP: $73.0M • VOL: 1.11M
52W L $0 52W H $4
ROARABLE / RQD
D- • 42/100
PIOTROSKI
3 / 9
NMRA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$241.2M | -$263.5M | -$252.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | $236.9M | $243.8M | -$235.9M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$206.4M | -$182.9M | -$163.3M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$206.4M | -$182.9M | -$163.3M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $182.5M | $142.1M | — |
| Total Debt (Short + Long Term) | $54.5M | $0 | — |
| Total Stockholders' Equity | $103.9M | $287.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NMRA.